Human LAG3 & IL-2 Reporter Recombinant Cell Line, Jurkat (CAT#: IOC-LX155)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant Jurkat T cell expressing firefly luciferase gene under the control of IL-2 response promoter with constitutive expression of human LAG3 (lymphocyte-activation gene 3, CD223, GenBank Accession # NM_002286). Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

• Screen for activators or inhibitors of LAG3 signaling in a cellular context
• Characterize the biological activity of LAG3 and its interactions with ligands

Human

Jurkat

LAG3 & IL-2 Reporter

Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its main ligand is MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T cells in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. A number of LAG3 antibodies are in preclinical development for treatments for cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints are only activating effector T cells, and not inhibiting Treg activity while an antagonist LAG3 antibody can both activate effector T cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.